In 2025, the global functional mushroom market is worth an estimated $34.62 billion, and it is on pace to more than double by 2035 [1]. Walk into a coffee shop in Brooklyn, a co-op in Bristol, or a health-food store in Brisbane and you will see the same cluster of jars: lion's mane for focus, reishi for calm, chaga for antioxidants, cordyceps for energy. The marketing is consistent. The science, as is so often the case in this corner of the supplement world, is messier.
Lion's mane: the cognitive frontrunner, with a small asterisk
Hericium erinaceus is the mushroom with the most flattering (and the most cited) human trial. In 2009, Koichiro Mori and colleagues at a Japanese clinic ran a 16-week, double-blind, placebo-controlled study of 30 men and women aged 50 to 80 with mild cognitive impairment [2]. Participants ate four 250 mg tablets of 96% Yamabushitake (the Japanese name for the species) dry powder three times a day, totalling 3 g per day. By week 8 the lion's mane group was scoring significantly higher on a standard dementia scale (the Revised Hasegawa Dementia Scale) than the placebo group, and the gap kept widening through week 16. Four weeks after they stopped taking the pills, their scores dropped back down, which suggests the effect is real but depends on continued use.
The trial itself is well-designed and produced a clean result, but it also remains the only one of its size. A separate 2010 study of menopausal women (and a smaller group of younger controls) reported reductions in self-reported depression and anxiety scores after four weeks of eating lion's mane cookies and jelly, though the design was not a full modern randomised controlled trial and the sample was small [3]. Beyond those two, the human literature thins out fast.
The mechanism you hear about most is nerve growth factor (NGF), a protein that supports the survival of certain neurons. Two classes of lion's mane compounds, hericenones from the fruiting body and erinacines from the mycelium, can stimulate NGF synthesis in cell culture and in rodents. Genuinely interesting, but the gap between "stimulates NGF in a dish of mouse astrocytes" and "rebuilds your hippocampus" is what most of the shelf-talkers quietly skip over. The evidence is thinner than the marketing suggests.
Reishi: the immune-tonic tradition vs. the clinic
Ganoderma lucidum, called lingzhi in Mandarin and reishi in Japanese, has been used in East Asian medicine for centuries, and it now holds the largest share of the functional mushroom market at roughly 21% of sales [1]. In the lab, reishi polysaccharides and triterpenes (the ganoderic acids) do interesting things to immune cells: they activate B and T lymphocytes, dendritic cells, macrophages, and natural killer cells, and they shift the release of cytokines such as IL-2, IL-6, TNF-α, and IFN-γ [4]. The immunomodulatory signal is real.
The trouble starts when you try to translate bench science into a clinic. Memorial Sloan Kettering's integrative medicine team, in their widely cited Reishi monograph, puts it bluntly: "Data in humans are limited and no conclusions can be drawn" [5]. Most clinical work has been in cancer-supportive care, where a small number of trials have reported modest improvements in quality-of-life measures, and a 2016 Cochrane-style review of five such trials found the evidence insufficient to support reishi for cancer-related fatigue [6]. A 2019 review of reishi's immunomodulation ends on the same note, calling for "evidence-based clinical trials" before mechanistic claims become clinical recommendations [4].
Reishi's side-effect profile is also worth flagging. Dizziness, dry mouth, and skin rash are common; rarer case reports have linked powdered reishi to liver toxicity at high doses, and reishi may interact with blood thinners, antiplatelet drugs, and immunosuppressants [5][6]. If you are on any of those, "natural" does not mean "safe to stack."
Chaga: antioxidants in a teacup, almost no human data
Inonotus obliquus is the black, crusty, cancer-like growth you find on birch trees in cold northern forests. Russians, Koreans, Chinese physicians, and several Indigenous Canadian groups have all used it [7]. Its dark pigment is rich in melanin. In cell culture and animal models, chaga extracts show antioxidant, anti-inflammatory, antiviral, and anti-tumor activity, with reported effects on melanoma and breast cancer cell lines, plus improved insulin sensitivity in diabetic mice.
The 2023 Frontiers in Pharmacology review, the most comprehensive recent synthesis, summarises the state of play plainly: chaga is a "promising natural resource" with a wide range of potential applications, and human clinical trials are scarce [7]. Chaga also accumulates oxalates, and chronic high-dose consumption has been linked in case reports to an increased risk of kidney stones, a caveat the supplement aisle rarely mentions. For a mushroom sold primarily as an antioxidant, the antioxidant story is mostly in a test tube.
Cordyceps: a real (if modest) exercise signal
Cordyceps is the genus best known for Ophiocordyceps sinensis, the parasitic fungus that infects ghost moth larvae on the Tibetan plateau and historically fetched extraordinary prices in traditional markets. Almost no commercial supplement contains wild-harvested cordyceps; most use the cultivated mycelium of a standardised strain called Cs-4 [8][9].
The most-cited human trial is a 2010 double-blind RCT by Chen and colleagues in 20 healthy older adults (aged 50 to 75) who took 3 g/day of Cs-4. The cordyceps group improved their VO2 max, the gold-standard measure of aerobic capacity, more than the placebo group, and reported better exercise tolerance on a treadmill [8][9]. A real result, if a modest one, in a small, older, sedentary population. It does not support the claim that cordyceps will turn a 28-year-old CrossFit athlete into a podium finisher, which is roughly what the marketing implies.
Cordyceps is generally considered safe, but the same drug-interaction caveats noted for reishi apply (with diabetes drugs added to the list), and there are case reports of allergic reactions in people sensitive to silkworm pupae, a cross-reactivity that makes biological sense given the fungus's life cycle [9]. Safety in pregnancy and breastfeeding has not been established.
Cutting through the marketing
Strip the wellness language off and the four mushrooms sit in different places on the evidence ladder. Lion's mane has the cleanest cognitive data, in older adults with mild impairment, with a plausible NGF mechanism behind it. Reishi's bench science on immune modulation runs deepest, but the human evidence lags badly behind. Chaga, meanwhile, leans on the most folklore and the least human data, with an oxalate caveat the supplements rarely mention. Cordyceps rounds things out with one respectable exercise trial in older adults and a caterpillar-fungus origin story that does most of the marketing's heavy lifting.
Practically speaking, the gap between a promising petri dish and a working human therapy is large, and the supplement industry is not always keen to remind you of that. If you are curious, the lion's mane trial is the one most likely to be replicated, and the Mori protocol used in the trial was 3 g/day of dried fruiting body. If you are considering lion's mane, any decision should be discussed with a clinician, particularly if you are on blood thinners or immunosuppressants, are pregnant, or have a mushroom or insect allergy. The rest of the claims will need better trials before they earn the confidence their labels project.